Real-world discontinuation of hepatitis C drugs was low, but it was 3 times more likely than in clinical trials and varied by patient characteristics.
Ping Du, MD, PhD
Advertisement
Articles by Ping Du, MD, PhD
This study analyzes the current coverage designs for hepatitis C virus drugs by Medicare Part D plans.
Advertisement
Latest Updated Articles
- Coverage for Hepatitis C Drugs in Medicare Part D
Published: May 3rd 2016 | Updated:
- Discontinuation of New Hepatitis C Drugs Among Medicare Patients
Published: February 12th 2020 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Zanubrutinib Safe, Effective in Real-World CLL/SLL Cohort
2
Promises and Pitfalls of AI in Health Care
3
Paul Ryan Champions Health Care Policy Reform, AI Amid Government Shutdown
4
Review Outlines Shared Pathways Between CKD, VHD
5
